Optimizing first-line TKI treatment efficacy in PD-L1-positive EGFR-mutated NSCLC: the impact of antiangiogenic agents

• Main Authors: Xuanhong Jin (Author), Yang Pan (Author), Cheng Cheng (Author), Hangchen Shen (Author), Chongya Zhai (Author), Kailai Yin (Author), Xinyu Zhu (Author), Hongming Pan (Author), Liangkun You (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

BackgroundIn individuals receiving treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), those exhibiting positive PD-L1 expression might experience reduced progression-free survival (PFS). However, the effects on overall survival (OS) and the determination of effic...